Wolfe Research initiated coverage of Avidity Biosciences (RNA) with an Outperform rating and $55 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Promising Developments in Avidity Biosciences’ FSHD Program Justify Buy Rating
- Avidity Biosciences initiated with a Strong Buy at Raymond James
- Avidity Biosciences Holds 2025 Annual Stockholder Meeting
- Avidity Biosciences: Promising Developments and FDA Endorsement Position for Potential Regulatory Approvals by 2027
- Avidity Biosciences price target raised to $75 from $70 at Citi